Navigation Links
David Burns Appointed CEO/President of Cellectricon
Date:9/20/2011

GOTHENBURG, Sweden, September 20, 2011 /PRNewswire/ --

Cellectricon appoints David Burns as the company's Chief Executive Officer. David brings a solid and highly impressive international Life Science executive track record to Cellectricon vital for the company's continued market expansion in bringing state-of-the-art screening solutions for drug discovery and cell-based research.

David Burns has extensive experience of the life sciences industry and has held executive management positions at Renishaw Diagnostics Ltd., Cyntellect Inc., GE Healthcare, Imaging Research Inc, BioSignal Packard Inc., and Pharmacia / LKB Ltd. Significantly; Mr. Burns has previously developed several companies through to outstanding commercial success.

Cellectricon's Chairman Axel Broms said: "The board is delighted with the appointment of David as the new CEO. We are looking forward to working with him in formulating and broadening the product offering using the Company's strong IP and technology position. David's experience in both research instruments and service businesses complements Cellectricon's strategic aim to deliver more value to its customers by offering assay development services based on Cellectricons in-house technology expertise in addition to instrument sales."

David Burns added:  "Cellectricon is a remarkable company with strong customer validation and well-earned reputation for providing groundbreaking products and services to the pharmaceutical and biotechnology industries. I will focus on providing strategic, operational, and customer relationship continuity. This will ensure that our customers can depend on Cellectricon to accelerate their drug discovery and biological research by continued development of new products and services, as well as an outstanding customer support. "

About Cellectricon

Cellectricon AB, Sweden, is a leading life sciences solutions provider of advanced screening products and services to accelerate drug discovery and cell-based assay research. The company is a total solutions provider of customized instruments to discovery services solving critical bottlenecks in drug discovery & cell based research. The proprietary technologies include industry leading platforms for high resolution ion-channel screening, and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess®HT System enables high throughput transfection for genomic screening and the new Dynaflow®HT System greatly advances ion channel drug discovery.


'/>"/>
SOURCE Cellectricon
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
3. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
8. David H. Murdock Research Institute Taps Waters for Laboratory Technology
9. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
11. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... April 27, 2016 , ... NDA Partners Chairman Carl ... an Expert Consultant. Mr. Clark was formerly a Vice President with US ... small molecule monographs based on analytical methods. NDA Partners Expert Consultants are ...
(Date:4/27/2016)... ... ... Global Stem Cells Group CEO Benito Novas announced that Duncan ... affiliate Kimera Labs in Miami. , In 2004, Ross received his Ph.D. in Immunology ... disorders and the suppression of graft vs. host disease (GVHD) under UM Professor Robert ...
(Date:4/27/2016)... , April 27, 2016 ... report with specific focus on US, EU, ... , to the healthcare business intelligence collection ... Complete report on the Flow Cytometry ... and supported with 282 tables and figures is ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):